New evidence

A meta-analysis tied Lactobacillus acidophilus L-92 to a 41% lower risk of gut side effects during cancer treatment — but didn’t find any improvement in how well patients actually responded to the cancer therapy itself.

This is the first solid evidence linking this specific probiotic to fewer bouts of diarrhea, constipation, nausea, and vomiting in people undergoing cancer treatment, but because it's an early meta-analysis with a small sample (37 participants, and the individual studies disagree a lot), the finding needs replication before you'd act on it.

The analysis pooled data from 37 people and found that taking L. acidophilus L-92 cut the overall risk of common gastrointestinal side effects like diarrhea and nausea by 41%. However, the same analysis found no evidence that the probiotic improved patients' actual cancer treatment response, so the benefit appears limited to reducing discomfort rather than boosting treatment success.

Where this fits in the evidence

This is among the first studies we've indexed on Lactobacillus acidophilus L-92 for Reduced Gastrointestinal Adverse Events — treat it as an early signal until more research accumulates.

The study

Interventions Targeting the Gut Microbiome to Improve Cancer Treatment Outcomes and Their Gastrointestinal Side Effects: A Systematic Review and Meta-analysis.

Meta-Analysis
n = 37
2026-02
The Journal of nutrition

More on Lactobacillus acidophilus L-92 More on Reduced Gastrointestinal Adverse Events

This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.